ELACESTRANT

AssetAlso called RAD1901, RAD-1901

Selectively binds estrogen receptor alpha, antagonizing its signaling and promoting its degradation.

Stage
Approved
Modality
Small molecule
Target
ESR1
6
Indications
37
Trials
2
Developers

Approved by the FDA on Jan 27, 2023 (NDA217639). 2 approvals stand. FDA

Indications

6
  • Er-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer

    Approved, FDA

  • Advanced or Metastatic Breast Cancer

    Approved, FDA

  • Breast neoplasm

    Approved, EMA

3 more

In the full profile

  • Target and mechanism1
  • Owner and partners2
  • Trials37
  • Evidence for its targets1
  • Competitors12
  • Signals5

Every asset’s record: target, stage, trials and the evidence behind it.

See Pro

Assets